ABSTRACT
Diesel vehicles have caused serious environmental problems in China. Hence, the Chinese government has launched serious actions against air pollution and imposed more stringent regulations on diesel vehicle emissions in the latest China VI standard. To fulfill this stringent legislation, two major technical routes, including the exhaust gas recirculation (EGR) and high-efficiency selective catalytic reduction (SCR) routes, have been developed for diesel engines. Moreover, complicated aftertreatment technologies have also been developed, including use of a diesel oxidation catalyst (DOC) for controlling carbon monoxide (CO) and hydrocarbon (HC) emissions, diesel particulate filter (DPF) for particle mass (PM) emission control, SCR for the control of NOx emission, and an ammonia slip catalyst (ASC) for the control of unreacted NH3. Due to the stringent requirements of the China VI standard, the aftertreatment system needs to be more deeply integrated with the engine system. In the future, aftertreatment technologies will need further upgrades to fulfill the requirements of the near-zero emission target for diesel vehicles.
Subject(s)
Air Pollutants , Air Pollution , Air Pollutants/analysis , Vehicle Emissions/prevention & control , Vehicle Emissions/analysis , Air Pollution/prevention & control , Air Pollution/analysis , Catalysis , China , Gasoline , Particulate Matter/analysis , Motor VehiclesABSTRACT
The aim of our study was to detect the expression of KIF23 in human bladder cancer tissues and to assess the potential role of KIF23 in bladder cancer progression. The expression of KIF23 and the correlation with bladder cancer patients were explored using the TCGA database. Additionally, IHC assays were also performed to detect KIF23 expression in 95 bladder cancer tissues and corresponding non-tumor tissues collected in our hospital. Colony formation, MTT, and flow cytometry (FCM) assays were performed to detect its effects on bladder cancer cell proliferation and apoptosis, respectively. An animal model was developed to found the effects of KIF23 on tumor growth in mice. Data showed that the KIF23 expression was upregulated in human bladder cancer tissues. The expression of KIF23 was correlated with the prognosis and clinicopathological features, including T stage (p=0.022) and recurrence (p=0.020), of bladder cancer patients. KIF23 depletion inhibited the proliferation of bladder cancer cells, stimulated apoptosis, and suppressed tumor growth in mice. We demonstrated the involvement of KIF23 in bladder cancer progression and provided a promising therapeutic target for the treatment of bladder cancer.
Subject(s)
Urinary Bladder Neoplasms , Animals , Cell Line, Tumor , Cell Proliferation , Gene Expression Regulation, Neoplastic , Humans , Kinesins/genetics , Mice , Microtubule-Associated Proteins/genetics , Neoplasm Recurrence, Local , Urinary Bladder Neoplasms/geneticsABSTRACT
The purpose of this study was to evaluate the efficacy of a 980-nm diode laser coagulation in women with radiation-induced hemorrhagic cystitis (RHC). We conducted a retrospective study of 21 RHC patients treated with a 980-nm diode laser between July 2014 and December 2017 at our institution. Data was collected with regard to age, sex, lower urinary tract symptoms, use of transfusions, a drop in hemoglobin levels, indication of radiotherapy, median time between radiation therapy and presentation, previous treatments, operative time, mean energy used, number of coagulated areas, catheterization time, discharge time after treatment, hospital stay, and surgical outcome. All 21 patients were women with a median age of 52 years (range 36-68 years). Eighteen patients complained of frequency and urgency, four patients had dysuria, and one patient developed urinary retention. Radiation therapy was primarily indicated in the treatment of cervical cancer in 18 patients (85.7%) and endometrial cancer in three patients (14.3%). Nine patients (42.8%) received blood transfusion before surgery and three patients (14.3%) needed blood transfusion after the procedure. The mean decrease in hemoglobin prior to the procedure was 4.08 ± 2.04 g/dL. The median length of time from completion of radiotherapy to the presentation of hematuria was 38 months (range 8-65 months). All patients had failed an adequate trial of conservative treatment which included adequate hydration, hemostatics, continuous bladder irrigation (CBI), and clot evacuation at the bedside. Eleven patients (52.4%) had previously been treated with endoscopic electrocoagulation; the mean number of procedures was 1.73 ± 0.78 (range 1-3 sessions). Six patients (28.6%) underwent HBO, and sodium hyaluronate solution irrigation was administered to 3 patients (14.3%). The mean number of HBO sessions was 26.3 ± 16.8 (range 8-50), and the mean number of sodium hyaluronate solution irrigation procedures was 4.33 ± 1.53 (range 3-6). All operations were successful. The mean operative time was 45.6 ± 12.3 min, the mean number of coagulated areas was 11.7 ± 4.4, the mean energy used was 2.74 ± 1.14 kJ, the mean catheterization time was 6.2 ± 0.9 days, the mean discharge time after treatment was 6.8 ± 1.2 days, and the average length of a hospital stay was 7.4 ± 1.3 days. In 16 patients (76.2%), hematuria was completely resolved after one session of diode laser coagulation. Four patients (19.0%) underwent multiple sessions of laser treatment due to recurrent gross hematuria (three patients required two sessions and one patient required three sessions). Only one patient (4.8%) who had persistent gross hematuria after diode laser treatment (two sessions) underwent a radical cystectomy, which resolved the hematuria. The median hematuria-free interval of patients who had multiple procedures was 9 months (range 1-13 months). In total, 21 patients underwent 27 sessions of diode laser coagulation, and the median hematuria-free interval was 16 months (range 1-45 months) with a median follow-up of 25 months (range 7-48 months). Our study shows promising results for the management of patients with RHC; however, further evaluation with a larger cohort is required to confirm the efficacy of this treatment.
Subject(s)
Cystitis/etiology , Cystitis/surgery , Hemorrhage/etiology , Hemorrhage/surgery , Laser Coagulation , Lasers, Semiconductor , Radiation Injuries/surgery , Adult , Aged , Cystitis/diagnostic imaging , Female , Hemorrhage/diagnostic imaging , Humans , Laser Coagulation/adverse effects , Lasers, Semiconductor/adverse effects , Middle Aged , Retrospective StudiesABSTRACT
OBJECTIVE: To compare the clinical effect of diode laser enucleation of the prostate (DIOD) with that of transurethral resection of the prostate (TURP) on benign prostate hyperplasia (BPH) with different prostate volumes. METHODS: This retrospective study included 256 BPH patients treated by DIOD (n = 141) or TURP (n = 115) from March 2012 to August 2015. According to the prostate volume, we divided the patients into three groups: <60 ml (42 for DIOD and 31 for TURP), 60ï¼80 ml (51 for DIOD and 45 for TURP), and >80 ml (48 for DIOD and 39 for TURP). We obtained the relevant data from the patients before, during and at 6 months after surgery, and compared the two surgical strategies in operation time, perioperative levels of hemoglobin and sodium ion, post-operative urethral catheterization time and bladder irrigation time, pre- and post-operative serum PSA levels, International Prostate Symptoms Score (IPSS), post-void residual urine (PVR) volume and maximum urinary flow rate (Qmax), and incidence of post-operative complications among different groups. RESULTS: In the <60 ml group, there were no remarkable differences in the peri- and post-operative parameters between the two surgical strategies. In the 60ï¼80 ml group, DIOD exhibited a significant superiority over TURP in the perioperative levels of hemoglobin (ï¼»3.25 ± 1.53ï¼½ g/L vs ï¼»4.77 ± 1.67ï¼½ g/L, P <0.05) and Na+ (ï¼»3.58 ± 1.27ï¼½mmol/L vs ï¼»9.67 ± 2.67ï¼½ mmol/L, P <0.01), bladder irrigation time (ï¼»30.06 ± 6.22ï¼½h vs ï¼»58.32 ± 10.25ï¼½ h, P <0.01), and urethral catheterization time (ï¼»47.61 ± 13.55ï¼½ h vs ï¼»68.01 ± 9.69ï¼½ h, P <0.01), but a more significant decline than the latter in the postoperative PSA level (ï¼»2.34 ± 1.29ï¼½ ng/ml vs ï¼»1.09 ± 0.72ï¼½ ng/ml, P <0.05), and similar decline was also seen in the >80 ml group (ï¼»3.35 ± 1.39ï¼½ ng/ml vs ï¼»1.76 ± 0.91ï¼½ ng/ml, P <0.05). No blood transfusion was necessitated and nor postoperative transurethral resection syndrome or urethral stricture observed in DIOD. However, the incidence rate of postoperative pseudo-urinary incontinence was significantly higher in the DIOD (22.7%, 32/141) than in the TURP group (7.83%, 9/115) (P <0.05). CONCLUSIONS: DIOD, with its obvious advantages of less blood loss, higher safety, faster recovery, and more definite short-term effectiveness, is better than TURP in the treatment of BPH with medium or large prostate volume and similar to the latter with small prostate volume.
Subject(s)
Lasers, Semiconductor/therapeutic use , Prostatic Hyperplasia/surgery , Transurethral Resection of Prostate/methods , Humans , Lasers, Semiconductor/adverse effects , Male , Operative Time , Organ Size , Postoperative Complications/etiology , Prostate/pathology , Prostatic Hyperplasia/pathology , Quality of Life , Retrospective Studies , Therapeutic Irrigation , Transurethral Resection of Prostate/adverse effects , Transurethral Resection of Prostate/statistics & numerical data , Treatment Outcome , Urethral Stricture/etiology , Urinary Catheterization , Urinary Incontinence/etiologyABSTRACT
Human urinary bladder cancer (UBC) is the one of the most common malignancies worldwide and occurs at a higher frequency in male individuals. ATP-binding cassette, subfamily C, member 3 (ABCC3), a member of the ABC transporter family, is highly expressed in tumor cells, where it actively effluxes a broad spectrum of metabolites. However, the expression and role of ABCC3 in human UBC remains unclear. Our study aimed to identify the expression status of ABCC3 in UBC cases and investigate the biological effects on UBC in cells. We found that both mRNA and protein levels of ABCC3 were significantly higher in UBC tissues than normal tissues. Immunochemistry evaluation of ABCC3 expression in 122 UBC clinical specimens showed that high expression of ABCC3 had a positive correlation with UBC tumor size, advanced tumor node metastasis stage, and malignant histology. Moreover, high ABCC3 expression was linked to poor overall survival in UBC. ABCC3 effects on cell proliferation and drug resistance were measured by colony formation and methylthiazolyldiphenyl-tetrazolium bromide (MTT) assays. ABCC3-knockdown cells showed a significant decrease in cell growth and drug resistance. RNA interference of ABCC3 also caused downregulation of lactate dehydrogenase A (LDHA), which positively correlated with ABCC3 expression in UBC specimens. In addition, cancer cell glycolytic ability was decreased upon ABCC3 knockdown. The activity of LDHA was also abrogated in ABCC3-deficient UBC cells, and the blockade of LDHA increased UBC cells sensitivity to Cis-diamine dichloroplatinum (CDDP). In summary, our study suggests ABCC3 is an important oncoprotein involved in glycolysis and drug resistance. These data also indicates that ABCC3 could be a potential prognostic marker and promising therapeutic target in UBC.
Subject(s)
Biomarkers, Tumor/genetics , Cell Proliferation , Drug Resistance, Neoplasm/genetics , Gene Expression Regulation, Neoplastic/physiology , Glycolysis/genetics , Multidrug Resistance-Associated Proteins/genetics , Urinary Bladder Neoplasms/genetics , Aged , Blotting, Western , Cell Line, Tumor , Female , Humans , Immunohistochemistry , Male , Middle Aged , Prognosis , Real-Time Polymerase Chain Reaction , Urinary Bladder Neoplasms/drug therapy , Urinary Bladder Neoplasms/pathologyABSTRACT
PURPOSE: Neutrophil gelatinase associated lipocalin, also known as lipocalin-2, is a 25 kDa protein now considered the biochemical gold standard for the early diagnosis of acute kidney injury. Recently lipocalin-2 was suggested to have an important role in several human neoplasias. In this study we assess lipocalin-2 expression in 2 renal tumor types and analyze its association with clinicopathological parameters and prognosis. MATERIALS AND METHODS: The study group included 189 patients who underwent surgery for renal lesions between 2003 and 2013. Of these patients 105 had clear cell renal cell carcinoma and 84 had papillary renal cell carcinoma. The association of lipocalin-2 immunoexpression and clinicopathological characteristics was evaluated. Cox proportional hazard regression was performed to estimate the prognostic significance of potential confounders in predicting overall and disease-free survival. RESULTS: Lipocalin-2 expression in different histotypes of analyzed tumors was highly and significantly associated with papillary renal cell carcinoma (p <0.001). In papillary renal cell carcinoma high lipocalin-2 expression was associated with high Fuhrman grade (p <0.001), tumor size greater than 7 cm (p = 0.007), increased TNM stage (p <0.001) and lymph node metastasis (p = 0.009). On univariable and multivariable Cox survival analyses of papillary renal cell carcinoma, after a median followup of 49.1 months (range 7 to 136) lipocalin-2 expression was associated with reduced overall survival (HR 4.10, 95% CI 1.19-14.14, p = 0.026) and disease-free survival (HR 2.56, 95% CI 1.01-6.48, p = 0.047). CONCLUSIONS: Lipocalin-2 over expression may be a prognostic factor in decreased overall and disease-free survival in papillary renal cell carcinoma. The association of lipocalin-2 over expression and poor prognosis with papillary renal cell carcinoma may have potential diagnostic and therapeutic utility.
Subject(s)
Acute-Phase Proteins/biosynthesis , Carcinoma, Renal Cell/metabolism , Kidney Neoplasms/metabolism , Lipocalins/biosynthesis , Proto-Oncogene Proteins/biosynthesis , Acute-Phase Proteins/analysis , Carcinoma, Renal Cell/chemistry , Carcinoma, Renal Cell/mortality , Female , Humans , Kidney Neoplasms/chemistry , Kidney Neoplasms/mortality , Lipocalin-2 , Lipocalins/analysis , Male , Middle Aged , Prognosis , Proto-Oncogene Proteins/analysis , Retrospective Studies , Survival RateABSTRACT
OBJECTIVE: To study the safety and effectiveness of laparoscopic radiofrequency ablation for centrally located renal tumors. METHODS: From January 2009 to April 2013, thirteen patients who diagnosed as centrally located renal tumors were treated with laparoscopic radiofrequency ablation in the Department of Urology of Nanjing Drum Tower Hospital Affiliated to Nanjing University Medical School. All of the cases were T1aN0M0 stage, 9 patients were male, 4 were female, the mean age was 56 years (range, 38-73 years). All tumors were unilateral, eight lesions were in the left kidney and five in the right kidney. Intraoperative real-time ultrasound and temperature probes were used to guide the range of radiofrequency ablation. Ice saline was injected through ureteral catheter for cooling the collecting system. The postoperative serum creatinine and glomerular filtration rate (GFR) data were collected,all patients were followed up with enhanced CT or MRI.The pre- and post-operative date were compared by paired t test. RESULTS: All patients underwent laparoscopic radiofrequency ablation successfully. The mean operation time was (113±13) minutes and the mean blood loss was (99±23) ml. The mean pre- and post-operative serum creatinine was (71±11) µmol/L and (74±11) µmol/L, the mean pre- and post-operative GFR was (49±8) ml/min and (45±7) ml/min. There was no significant statistic difference between pre-operation and post-operation (t=-1.371 and 1.986, P>0.05). The mean follow-up was 37 months, range 12-63 months. No evidence of local recurrence or distant metastasis was found. CONCLUSIONS: Laparoscopic radiofrequency ablation for T1aN0M0 centrally located renal tumors could be performed safely with good outcomes. Intraoperative real-time ultrasound and temperature probes are helpful to control the range of radiofrequency ablation. Physical cooling of renal collecting system could reduce the occurrence of postoperative hydronephrosis and leakage of urine.
Subject(s)
Catheter Ablation , Kidney Neoplasms/therapy , Laparoscopy , Adult , Aged , Female , Glomerular Filtration Rate , Humans , Kidney , Magnetic Resonance Imaging , Male , Middle Aged , Neoplasm Recurrence, Local , Operative Time , Postoperative Period , Treatment OutcomeABSTRACT
Human cystatin C (CYSC) is a 13-kDa endogenous cysteine proteinase inhibitor and was investigated as a replacement for creatinine as a marker of renal function. However, expressing recombinant CYSC is difficult in Escherichia coli because of resulting low yield and insufficient purity and insolubility. Here, we cloned and fused CYSC to the C-terminus of three soluble partners - maltose-binding protein (MBP), glutathione S-transferase (GST) and translation initiation factor 2 domain I (IF2) - to screen for their ability to improve the solubility of recombinant CYSC when expressed in E. coli. MBP was best at enhancing the soluble expression of CYSC, with soluble fractions accounting for 92.8±3.11% of all proteins. For scaled production, we purified the de-tagged CYSC by using a 3C protease-cleaved MBP-T3-CYSC fused protein with immobilized metal affinity chromatography and cation-affinity purification. The molecular weights of the de-tagged CYSC and human natural CYSC were similar, and the former could react specifically with CYSC polyclonal antibody. Moreover, the de-tagged CYSC displayed full biological activity against papain and cathepsin B, which was very similar to that of the human natural CYSC protein standard. We provide a method to produce large amounts of soluble recombinant human CYSC in E. coli.
Subject(s)
Cystatin C/biosynthesis , Maltose-Binding Proteins/genetics , Recombinant Fusion Proteins/biosynthesis , Cathepsin B/metabolism , Chromatography, Affinity , Cystatin C/genetics , Cystatin C/isolation & purification , Escherichia coli , Glutathione Transferase/genetics , Humans , Papain/metabolism , Prokaryotic Initiation Factor-2/genetics , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/isolation & purification , SolubilityABSTRACT
OBJECTIVE: To explore the causal relationship between cystatin C levels and different stages of diabetic retinopathy through Mendelian randomization (MR). METHODS: The MRC Integrative Epidemiology Unit provided the Genome-wide association studies (GWAS) data related to cystatin C (exposure). GWAS data for outcomes [DR, proliferative diabetic retinopathy (PDR), severe non-proliferative background diabetic retinopathy (SNPBDR)] were sourced from the FinnGen. Adopted Inverse Variance Weighting (IVW), MR-Egger regression MR-PRESSO, Weighted Median, Constrained Maximum Likelihood and Model Averaging (cML-MA), Weighted model, Radial MR, and MR-Lasso to estimate the causal relationship between cystatin C and diabetic retinopathy. We conducted multivariable MR analysis to evaluate the independent causal effects of cystatin C levels on diabetic retinopathy. RESULTS: Based on the IVW method, we observed a causal relationship between cystatin C and diabetic retinopathy [odds ratio (OR)random effect = 1.137, 95% confidence interval (CI): 1.035-1.250]/PDR (ORrandom effect = 1.123, 95%CI: 1.004-1.255)/SNPBDR (ORfixed effect = 2.002, 95%CI: 1.343-2.986). Consistent findings were obtained through the cML-MA method. Cochran's Q test suggested the presence of heterogeneity between the cystatin C level and instrumental variables in relation to diabetic retinopathy and proliferative diabetic retinopathy, respectively. After adjusting for outliers using MR-PRESSO and Radial MR, it was observed that the statistical significance of the association between cystatin C level and diabetic retinopathy persists. Reverse MR analysis indicated that genetically related SNPBDR may influence the cystatin C level. In multivariable MR analysis, there were indications suggesting a causal relationship of cystatin C with the risk of DR/PDR/SNPBDR adjusting for confounders. CONCLUSIONS: This study utilizes Mendelian randomization analyses to establish a causal relationship between cystatin C and diabetic retinopathy, and reveals the impact of cystatin C on the risk of diabetic retinopathy, thus providing new evidence for clinical intervention of diabetic retinopathy.
ABSTRACT
CLINICAL RELEVANCE: Investigating the role of dietary vitamin B6 intake in the risk and prognosis of diabetic retinopathy (DR) could facilitate the management of DR. BACKGROUND: This study aimed to assess the association between dietary vitamin B6 intake and the risk of DR and further explore the association between vitamin B6 intake and mortality in patients with DR. METHODS: This retrospective cohort study gained data from the National Health and Nutrition Examination Survey (NHANES) 2005-2006 and 2007-2008. The intake of dietary vitamin B6 was assessed by two 24-h dietary recall interviews. Mortality information in the National Death Index was recorded from the date of survey participation through 31 December 2019. Multivariate regression analyses were employed to assess the association between vitamin B6 intake and the risk of DR, and the association between vitamin B6 intake and the risk of mortality in patients with DR. RESULTS: A total of 5559 subjects were included, of which 693 (12.47%) had DR. Among these patients with DR, 429 (61.90%) were survivors. Multivariate analyses showed that the intake of vitamin B6 was negatively associated with the risk of DR (odds ratio = 0.81, 95% confidence level: 0.69-0.95, p = 0.012), and patients with DR with an increased intake of vitamin B6 had a significantly decreased risk of all-cause death (hazard ratio = 0.81, 95% confidence level: 0.66-0.99, p = 0.041) or cardiovascular disease-related death (hazard ratio = 0.76, 95% confidence level: 0.58-0.98, p = 0.037). CONCLUSION: The intake of vitamin B6 was negatively associated with the risk of DR, and in patients with DR, a higher intake of vitamin B6 was associated with a lower risk of all-cause death and cardiovascular disease-related death, indicating the possible protective role of increased vitamin B6 intake.
ABSTRACT
Aim: The objective of this study is to investigate the relationship between visceral fat area (VFA) and diabetic retinopathy (DR) in the context of type 2 diabetes mellitus (T2DM) within Ningbo, China. Methods: The data of a total of 3,707 subjects with T2DM treated at The First Affiliated Hospital of Ningbo University were enrolled. The existence and severity of diabetic retinopathy were assessed by employing the 45° two-field stereoscopic digital photography. Subjects were categorized into four distinct groups: those without DR (NDR), individuals with mild non-proliferative DR (mild NPDR), people with moderate non-proliferative DR (moderate NPDR), and those suffering from vision-threatening DR (VTDR). Bio-electrical impedance was employed to estimate the Visceral fat area (VFA). Multinomial logistic regression models were utilized to evaluate the association between VFA and DR. Results: The mean VFA in patients without diabetic retinopathy (NDR) was notably lower compared to that of patients with diabetic retinopathy (DR) (85.21 ± 37.78 vs. 97.37 ± 44.58 cm2, p < 0.001). As the severity of DR increased, VFA increased gradually but insignificantly (94.41 ± 43.13 cm2, 96.75 ± 40.82 cm2, 100.84 ± 49.34 cm2, p = 0.294). After adjusting the confounding factors, there was an association identified between VFA and the occurrence of DR (OR = 1.020, 95% CI = 1.016-1.024). It showed that regardless of BMI, whether it's less than 25 kg/m2 or greater than or equal to 25 kg/m2, a higher VFA (≥100 cm2) level came with a higher prevalence of DR (p < 0.001). Conclusion: The outcomes of this research indicate a modest association between VFA and the incidence of DR among Chinese patients who have been diagnosed with T2DM in Ningbo.
ABSTRACT
Based on the activity evaluation and characterization test, we explored the hydrothermal aging mechanism of a vanadium-based SCR catalyst and constructed a dual-site hydrothermal aging kinetic model in this study. The vanadium-based catalyst contains Brønsted acidic sites and Lewis acidic sites, which show different sensitivities to hydrothermal aging, and the reduction of active sites is the main reason for the NOx conversion efficiency reduction after hydrothermal aging. The ammonia storage capacities of both sites have a high correlation coefficient with the NOx conversion efficiency. Based on the method of NH3-TPD curve peak resolution, we quantified the transformations of the two active sites and established the relationship between the site density, the aging temperature, and the duration to determine the aging factor. Then, a hydrothermal aging kinetic model was constructed, and the parameter identification and verification of the model were carried out through flow reactor experiments. The results show that the model constructed in this study can accurately reflect the catalyst activity after hydrothermal aging.
ABSTRACT
Flesh color is an important quality of melon (Cucumis melo L.) and is determined mainly by carotenoid content, awarding them with colors, aromas, and nutrients. enhancing the nutritional and health benefits of fruits and vegetables for humans. In this study, we performed transcriptomic analysis of two melon inbred line "B-14" (orange-flesh) and "B-6" (white-flesh) at three developmental stages. We observed that the ß-carotene content of inbred line "B-6" (14.232 µg/g) was significantly lower than that of inbred line "B-14" (0.534 µg/g). RNA-sequencing and quantitative reverse transcription PCR analyses were performed to identify differentially expressed genes (DEGs) between the two inbred lines at different stages; the DEGs were analyzed using the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes databases (KEGG). We identified 33 structural DEGs in different developmental periods of the two lines that were related to carotenoid metabolism. Among them, PSY, Z-ISO, ZDS, CRTISO, CCD4, VDE1, and NCED2 were highly correlated with carotenoid content. Thus, this study provides a basis for molecular mechanism of carotenoid biosynthesis and flesh color in melon fruit.
Subject(s)
Cucurbitaceae , Fruit , Humans , Fruit/chemistry , Cucurbitaceae/genetics , Cucurbitaceae/metabolism , Carotenoids/metabolism , beta Carotene/metabolism , Gene Expression Profiling , Transcriptome , Gene Expression Regulation, PlantABSTRACT
BACKGROUND: Long noncoding RNAs (lncRNAs) have been regarded as crucial regulators in many cancers, including clear cell renal cell carcinoma (ccRCC). This research aimed to explore the biological role and molecular mechanism of lncRNA HCG18 in ccRCC. MATERIALS AND METHODS: The expression levels of HCG18, miR-152-3p and RAB14 were examined by RT-qPCR. Cell viability, migration and invasion were examined by CCK-8 and transwell assays. Luciferase reporter and RIP assays were adopted to verify the interaction between miR-152-3p and HCG18 or RAB14. RESULTS: It was found that HCG18 expression was highly expressed in ccRCC tissues and cells, and patients with high expression of HCG18 had a short overall survival time. Moreover, HCG18 depletion attenuated ccRCC cell viability, migration and invasion. In addition, miR-152-3p was confirmed as a downstream target of HCG18 and was inversely regulated by HCG18, and RAB14 was a target of miR-152-3p. Functional assays demonstrated that miR-152-3p silencing or RAB14 addition abolished the inhibitory effects of HCG18 knockdown on ccRCC progression. CONCLUSION: The results of the present study indicated that HCG18 accelerated the development and progression of ccRCC by upregulating RAB14 via sponging miR-152-3p, suggesting a potential therapeutic target for patients with ccRCC.
ABSTRACT
In this study, we selected basalt fiber (BF) as a functional filler to improve the mechanical properties of ethylene vinyl acetate (EVA)-based flame retardant materials. Firstly, BF was modified by grafting γ-aminopropyl triethoxysilane (KH550). Fourier transform infrared spectroscopy (FTIR), thermogravimetric analysis (TGA), scanning electron microscope (SEM), and energy dispersive X-ray spectroscopy (EDS) were used to comprehensively prove the successful modification of the BF surface. Subsequently, the modified BF was introduced into the EVA/magnesium hydroxide (MH) composites by melt blending. The limiting oxygen index (LOI), UL-94, cone calorimeter test, tensile test, and non-notched impact test were utilized to characterize both the flame retardant properties and mechanical properties of the EVA/MH composites. It was found that the mechanical properties were significantly enhanced without reducing the flame retardant properties of the EVA/MH composites. Notably, the surface treatment with silane is a simple and low-cost method for BF surface modification and the pathway designed in this study can be both practical and effective for polymer performance enhancement.
ABSTRACT
Considering the risks of hydrothermal deterioration in vehicles, power plants, and oceangoing vessels, V2O5-WO3/TiO2 catalysts were subject to hydrothermal and thermal aging at 600, 625, 635, and 650 °C for 4-48 h. The different ratio and significant loss of active sites are main reasons for catalyst deactivation. Both Lewis and Brønsted acid sites are involved in the selective catalytic reduction reaction. Brønsted acid sites are more susceptible. High temperature plays a major role in the aging. It causes sintering, particle growth, and the anatase phase transition. Phase transformation turns out to be less important than sintering. Sintering leads to the reduction of the BET surface area, which in turn causes decrease of NH3 adsorption amount and changes of active sites. Aging time can accelerate the degree of deactivation. It also helps to change the proportion of active sites. Water vapor has no significant effect on NO X conversion rates.
ABSTRACT
Bladder cancer is the second most common urological cancer worldwide with low early diagnosis and high mortality. Since the time of diagnosis directly affects survival rate, early detection and precise biomarkers of bladder cancer are very important. Adenylate kinase 4 (AK4) is a key enzyme involved in cellular metabolism and multiple cancer development; however, the potential role of AK4 in bladder tumorigenesis is still unclear. Immunohistochemistry assay was conducted to evaluate the expression level of AK4 in 107 human bladder cancer tissues. Overall survival and recurrence-free survival were used to assess the prognosis of patients. Colony formation and MTT assays [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide] were performed to measure the proliferation capacity of tumor cells. Cell scratch assays and transwell assays were performed to measure the invasion capacity of tumor cells. The expression level of involved genes was measured by reverse transcription-polymerase chain reaction and western blot assays. The animal model was used to examine the effects of indicated protein on tumorigenesis and invasion in vivo. Herein, our study demonstrated that increased AK4 expression in patients with bladder cancer was associated with a poor prognosis. We further found that inhibition of AK4 in bladder cancer cell line T24 and 5637 can obviously inhibit the proliferation of cancer cells. Transwell assay results showed that down-regulated AK4 was related to the decreased metastasis of T24 and 5637 cells. In addition, AK4-shRNA transfected obviously inhibited tumor growth and metastasis in mice compared with the scramble group. Taken together, the results provide strong evidence of the involvement of AK4 in the progression of bladder cancer and suggest that it could have high potential as a therapeutic target of disease.
Subject(s)
Adenylate Kinase/genetics , Adenylate Kinase/metabolism , Up-Regulation , Urinary Bladder Neoplasms/pathology , Animals , Cell Line, Tumor , Cell Movement , Cell Proliferation , Gene Expression Regulation, Neoplastic , Humans , Mice , Neoplasm Invasiveness , Neoplasm Transplantation , Prognosis , Survival Analysis , Urinary Bladder Neoplasms/genetics , Urinary Bladder Neoplasms/metabolismABSTRACT
We presented a rare case with giant ureteral polyp that mimics bladder tumor in adult women, originating from the middle segment of the left ureter. The patient was a 42-year-old woman, with a 2.1×1.3 cm bladder mass detected incidentally on a health screening ultrasound. Computerized tomography (CT) of the pelvis revealed a solid tumor situated near to trigon. Cystoscopy demonstrated a tumor that periodically prolapsed into the bladder. After the tumor was identified as a ureteral polyp by ureteroscopy, an ureteroscopic resection by diode laser was performed. The tumor measured 9.0×0.5 cm, and the final pathological diagnosis was ureteral fibroepithelial polyp. No recurrence was observed at the 5-month follow-up.
Subject(s)
Diagnosis, Differential , Polyps/pathology , Polyps/surgery , Ureteral Neoplasms/pathology , Ureteral Neoplasms/surgery , Ureteroscopy/methods , Adult , Female , Humans , Lasers, Semiconductor , Urinary Bladder Neoplasms/diagnosisABSTRACT
Renal angiomyolipomas (AML), consisting of fatty tissue, blood vessels, and smooth muscular cells in various proportions, is a relatively common benign renal neoplasm. Simultaneous involvement of the kidney and lymph nodes is uncommon and might be confused with an advanced renal cancer. AML is divided into minimal fat AML and fat-predominant AML. However, minimal fat AML with lymph node involvement is extremely rare and difficult to differentiate from RCC on images. We report such a case and review the literature.
ABSTRACT
We reported a case of metanephric adenofibroma in a 10-year-old boy to describe the clinical, radiologic, and pathologic features and discuss its treatment and differential diagnosis. Nephrectomy was performed for the patient; final histopathologic evaluation was that of a metanephric adenofibroma. Epithelial and stromal elements were both positive for WT-1, Vimentin, PAX2, and the epithelial tumor cells were also positive for S100, AE1/AE3, PAX8, CK8/18, EMA and a few cells were positive for CK7. Larger vessel wall components were positive for SMA, Des, caldesmon while capillary components were positive for CD10, CD31, and CD34. CA-9, α-inhibin and CD-56 were negative in the neoplasm. The Ki-67 labeling index was <1%. Metanephric adenofibroma is a rare benign renal tumor; the diagnosis of it relies on pathology and immunohistochemistry. As its rarity, there is no standard treatment for this disease. The majority of patients underwent nephrectomy and had good prognosis, as it is a benign neoplasm.